News | July 02, 2022
Lonza to invest 500 mn in commercial drug product fill & finish facility
The investment will enable the company to provide customers with a complete and integrated end-to-end solution
The investment will enable the company to provide customers with a complete and integrated end-to-end solution
H Clinical is the leader in decentralized clinical trial support and home visits in Latin America
HIL has set up the Bti bio-larvicide manufacturing facility at its Rasayani Plant at Maharashtra with the financial assistance of GEF/UNIDO under the project
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
TLANDO was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.
The refocused commercial set-up will increase organizational efficiency and alignment across all commercial functions globally
The drug will be available in 600 hospitals and 105 DTPs
HK inno.N Corporation will be responsible for the manufacture and supply of Tegoprazan, while Dr. Reddy's will handle local clinical development, registration, marketing and sales
Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
All the capex is being met through internal accruals only
Subscribe To Our Newsletter & Stay Updated
